Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

There's so much growth on the horizon for Eli Lilly, and with the stock's payout ratio still at a fairly modest 54% of earnings, there is more room for the business to continue making generous ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also means it's the ...

Eli Lilly's competitive position in the obesity market is discussed in today's article along with the potential for growth acceleration in 2025 and 2026 versus current expectations for moderating ...

Eli Lilly didn't generate much growth last year, but its future looks promising. Mounjaro has the potential to be a game-changing product for the business. It could significantly propel the ...

Moreover, Eli Lilly’s stock performance has sparked speculation about a potential split, though its last split occurred in 1997. So, there are plenty of potential catalysts ahead.

Investors looking for a stock that has crushed the market this year need look no further than pharmaceutical giant Eli Lilly (LLY 0.82%).The drugmaker has been on a tear on the back of excellent ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world. It's one that ...